Показать сообщение отдельно
  #15  
Старый 29.07.2011, 23:08
Аватар для Dr.Anisimova
Dr.Anisimova Dr.Anisimova вне форума ВРАЧ
Почетный участник форума
      
 
Регистрация: 16.01.2007
Адрес: РФ, ЛО
Сообщений: 14,320
Сказал(а) спасибо: 6
Поблагодарили 5,347 раз(а) за 4,983 сообщений
Dr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форумеDr.Anisimova этот участник имеет превосходную репутацию на форуме
Investigative guidelines for alopecia areata
Article first published online: 20 JUN 2011
http://onlinelibrary.wiley.com/doi/1...11.01415.x/pdf
http://onlinelibrary.wiley.com/doi/1...1.01415.x/full
The reported efficacy of various treatments for alopecia is difficult to compare based on a general lack of consideration in case reports/series and clinical trials of the spontaneous regrowth or baseline prognostic factors seen in alopecia areata and a general lack of quantification of hair growth. This report will give both the investigator and clinician guidelines for clinical trial design that will take into account variables known to effect efficacy results such as baseline severity, pattern, and duration of hair loss, age of the subject, and concomitant conditions that may impact on potential regrowth. Reliable methods of assessment of efficacy and response criteria that will enable direct comparison of results between agents will also be discussed.

Cardiomyopathy with Alopecia and Palmoplantar Keratoderma (CAPK) is caused by a JUP mutation
http://onlinelibrary.wiley.com/doi/1...11.10455.x/pdf
http://onlinelibrary.wiley.com/doi/1...ly+maintenance

linical profile and impact on quality of life: Seven years experience with patients of alopecia areata
linical profile and impact on quality of life: Seven years experience with patients of alopecia areata
http://www.ijdvl.com/article.asp?iss...ast=Al-Mutairi

Brain-derived nerve factor and neurotrophins in androgenetic alopecia.
http://www.ncbi.nlm.nih.gov/pubmed/2...?dopt=Abstract
http://dx.doi.org/10.1111/j.1365-2133.2011.10514.x
Conclusions: Neurotrophic factors, especially BDNF, may be important in mediating the effects of androgens on hair follicles, serving as a negative regulatory control signal. Further studies may lead to novel pharmacologic interventions in AGA.

Alteration in Hair Texture Following Regrowth in Alopecia Areata
http://archderm.ama-assn.org/cgi/con...11.192v1?rss=1
Conclusions* The precipitating factor for a change in hair texture in alopecia areata may be a result of treatment, pathophysiologic changes, or a combination of both. Whether the change is triggered at the level of stem cell differentiation, by cytokine or hormonal influences, gene expression during hair follicle development, a combination of all of these, or an unknown cause is a question that remains to be answered.

Alopecia areata: a new treatment plan
http://dovepress.com/alopecia-areata...d-article-CCID
(статью можно скачать полностью)

Alopecia: evaluation and treatment
http://dovepress.com/alopecia-evalua...d-article-CCID

Randomized, double-blind, split-side comparison study of moisturizer containing licochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic dermatitis
http://onlinelibrary.wiley.com/doi/1...1.04187.x/full
Conclusion Moisturizer containing 0.025% licochalcone had higher cure rate compared to 1% hydrocortisone for the treatment of ISD at day 3–4. However, by the end of the first week, this difference was no longer significant.